LNR-653.1

N/A

Report date: 2022/05/10 11:42:41

Base Information

Drug NameLNR-653.1

Drug Alias NameLNR-653.1BIOP-653.1

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionInterleukin 17A inhibitorsPlacental Growth Factor inhibitorsVascular endothelial growth factor inhibitors

TargetsPlacental Growth FactorVascular endothelial growth factorInterleukin 17A

Therapy Area/IndicationsPsoriasis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBiophtha Inc

China Registration ClassN/A

Develop Information

Active CompaniesLanier Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsPsoriasis

Inactive IndicationsN/A

Other Information

ATC CodeN/A